Beckman predicts surge in routine chemistry sales in H2
This article was originally published in Clinica
Beckman Coulter's immunodiagnostics and hematology units experienced the company's greatest quarterly growth rates, with sales increases of 10% and 11%, respectively. Despite flat growth, president and CEO John Wareham remained optimistic regarding the routine chemistry unit, claiming "sales in routine chemistry should pick up dramatically" in the second half, spurred on by a healthy hospital market and four supply contracts with Premier, worth over $173m over 21 months. Mr Wareham is anticipating full-year sales growth of 6-7% and net earnings to reach the expected 18-20%.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.